Baker Bros. Advisors LP Immatics N.V. Transaction History

Baker Bros. Advisors LP

$9.86 Billion
Q2 2025

A detailed history of Baker Bros. Advisors LP transactions in Immatics N.V. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 10,168,901 shares of IMTX stock, worth $111 Million. This represents 0.55% of its overall portfolio holdings.

Number of Shares

10,168,901

Previous 7,275,830 39.76%

Holding current value

$111 Million

Previous $32.8 Million 66.73%

% of portfolio

0.55%

Previous 0.39%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$3.5 - $6.14 $10.1 Million - $17.8 Million	2,893,071 Added 39.76%	10,168,901 $54.7 Million
Q4 2024 Feb 14, 2025	BUY	$6.73 - $11.21 $5.6 Million - $9.33 Million	832,432 Added 12.92%	7,275,830 $51.7 Million
Q1 2024 May 15, 2024	BUY	$10.23 - $12.94 $6.18 Million - $7.82 Million	604,545 Added 10.35%	6,443,398 $67.7 Million
Q4 2023 Feb 14, 2024	BUY	$7.36 - $10.89 $1.46 Million - $2.16 Million	198,037 Added 3.51%	5,838,853 $61.5 Million
Q2 2023 Aug 14, 2023	BUY	$5.92 - $12.72 $2.69 Million - $5.77 Million	453,735 Added 8.75%	5,640,816 $65.1 Million
Q4 2022 Feb 14, 2023	BUY	$8.05 - $11.58 $6.14 Million - $8.84 Million	763,350 Added 17.26%	5,187,081 $45.2 Million
Q3 2021 Nov 15, 2021	BUY	$11.58 - $15.46 $1.63 Million - $2.18 Million	140,793 Added 3.29%	4,423,731 $57.5 Million
Q2 2021 Aug 16, 2021	BUY	$10.43 - $12.81 $3.03 Million - $3.72 Million	290,182 Added 7.27%	4,282,938 $49.7 Million
Q1 2021 May 17, 2021	BUY	$10.24 - $14.6 $22.4 Million - $31.9 Million	2,187,731 Added 121.2%	3,992,756 $44.8 Million
Q4 2020 Feb 16, 2021	BUY	$9.67 - $12.05 $7.77 Million - $9.68 Million	803,611 Added 80.25%	1,805,025 $19.5 Million
Q3 2020 Nov 16, 2020	BUY	$8.73 - $15.15 $8.74 Million - $15.2 Million	1,001,414 New	1,001,414 $10.6 Million

Others Institutions Holding IMTX

# of Institutions

Shares Held

93.6M

Call Options Held

158K

Put Options Held

View Full List

About Immatics N.V.

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $835M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

More about IMTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.

Account

Baker Bros. Advisors LP Immatics N.V. Transaction History